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Abstract
Background: The objective of this study was to assess, whether right atrial (RA) and ventricular (RV) size is related
to RV pump function at rest and during exercise in patients with pulmonary arterial hypertension (PAH).
Methods: We included 54 patients with invasively diagnosed PAH that had been stable on targeted medication.
All patients underwent clinical assessments including right heart catheterization and echocardiography at rest
and during exercise. RV output reserve was defined as increase of cardiac index (CI) from rest to peak exercise
(ΔCIexercise). Patients were classified according to the median of RA and RV-area. RV pump function and further
clinical parameters were compared between groups by student’s t-test. Uni- and multivariate Pearson correlation
analyses were performed.
Results: Patients with larger RA and/or RV-areas (above a median of 16 and 20cm2, respectively) showed significantly
lower ΔCIexercise, higher mean pulmonary arterial pressure, pulmonary vascular resistance at rest and NT-proBNP levels.
Furthermore, patients with higher RV-areas presented with a significantly lower RV stroke volume and pulmonary
arterial compliance at peak exercise than patients with smaller RV-size. RV area was identified as the only independent
predictor of RV output reserve.
Conclusion: RV and RA areas represent valuable and easily accessible indicators of RV pump function at rest and during
exercise. Cardiac output reserve should be considered as an important clinical parameter. Prospective studies are needed
for further evaluation.
Keywords: Pulmonary hypertension, Right ventricular output reserve, Pump function, Right ventricular size, Right atrial size
Background
Pulmonary arterial hypertension (PAH) is a complex
cardiopulmonary disorder, characterized by progressive
changes affecting both the pulmonary vasculature and
the right heart [1, 2]. Although the initial pathological
changes occur on pulmonary arterioles causing increased
pulmonary vascular resistance (PVR), adaptation of right
ventricular (RV) pump function is a key determinant of
survival [2, 3]. Rising attention is drawn to the concept of
RV-arterial coupling, a composite measure of RV pump
function and ventricular load [4–6].
Right atrial (RA) [7–9] and RV size have repeatedly been
proven of prognostic significance in pulmonary hyperten-
sion [2, 10], whereas their impact on RV contractility re-
mains to be determined. Recent studies using magnetic
resonance imaging (MRI) have shown, that increased
RV-endsystolic or diastolic volumes were significantly re-
lated to a worse outcome and reduced RV stroke volume
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(SV) [11]. In a further study enlargement of RV volumes
during follow-up was associated with further clinical signs
of disease progression [12].
RV output reserve (ΔCIexercise) defined as increase of car-
diac output/cardiac index (CI) during exercise with normal
or elevated PVR measured by right heart catheterization
(RHC) is an emerging parameter which has shown to be
prognostically important in patients with PAH [13, 14]. It
solely displays the capacity of the right ventricle to adjust
its systolic function to a given level of pulmonary loading4.
Pulmonary arterial compliance (PAC) reflects the elasticity
of the pulmonary arteries. For estimation of pulmonary
arterial compliance (or capacitance) the measurement of
SV/pulse pressure (cardiac output/heart rate)/(systolicPAP-
diastolicPAP) by RHC has been shown to be the most sim-
ple and practical method [15, 16].
The objective of the study was to investigate the cor-
relation between right heart size (measured as right
atrial and ventricular area by echocardiography) and
RV pump function at rest and during exercise (assessed
by RHC) and further hemodynamic and clinical param-
eters. Furthermore, this study aimed to detect correla-
tions and determining factors of RV pump function.
Methods
Patient selection
We retrospectively reviewed all incident (i.e. newly
diagnosed) patients aged ≥18 to 80 years with idio-
pathic, heritable or drug- and toxin-induced or con-
nective tissue disease associated PAH who were
diagnosed at the PH-center in Heidelberg between
January 1st, 2016 and November 31st, 2016. Inclusion
required RHC at rest (confirming PAH, defined as a
mean pulmonary arterial pressure ⩾25 mmHg, pul-
monary arterial wedge pressure ⩽15 mmHg and PVR
> 3 Wood units [17], and during exercise. Diagnosis
of PAH was performed according to the ESC/ERS
guidelines [17].
Patients were excluded if they lacked a complete
evaluation including medical history, WHO/NYHA
functional class assessment, physical examination,
electrocardiogram, transthoracic 2D-echocardiography
at rest, lung function test, arterial blood gases, 6-min
walking distance (6MWD) under standardized condi-
tions [18], laboratory testing including NT-proBNP
levels. All examinations were performed at the Thor-
axklinik at Heidelberg University Hospital by experi-
enced physicians within 48 h from the right heart
catheterization.
Right heart catheterization
The hemodynamic values have been obtained by the
charts. The right heart catheterization has been per-
formed in a standardized way in a supine position
using the transjugular access with a triple-lumen
7F-Swan-Ganz thermodilution catheter at rest and
during exercise as previously described [19]. Patients
had been examined on a variable load supine bicycle
ergometer by experienced investigators (CN, BE, SH).
Pressures were continuously recorded and averaged
over several respiratory cycles during spontaneous
breathing, both at rest and during exercise. Cardiac
output (CO) was measured by thermodilution at least
in triplicate with a variation of less than 10% between
the measured values. The zero reference point for
pressure recordings was set at ½ of the thoracic diam-
eter below the anterior thorax surface [20]. After the
hemodynamic measurement at rest, the supine pos-
ition was changed to a 45° position. Calibration for ex-
ercise measurements were performed as previously
described [21]. The exercise test was started with a
workload of 25 W. Workload was incrementally in-
creased by 25 W every 2 min to an exercise capacity
or symptom limited maximum.
Echocardiography
Resting two dimensional transthoracic echocardiog-
raphy (TTE) Doppler examinations were performed by
experienced cardiac sonographers (EG, CN, BE, SH)
with commercially available equipment (Vivid 7, GE
Healthcare, Milwaukee, Wisconsin) according to stan-
dardized protocol as described previously [9, 22]. TTE
measurements were obtained off line from stored
DICOM data according to the European Association
of Cardiovascular Imaging (EACVI) Guidelines [23].
Specific indices included RA-/RV-area, TAPSE and
PASP at rest. For all calculations the mean value of at
least 3 measurements was used. PASP was estimated
from peak tricuspid regurgitation jet velocities (TRV)
according to the equation: PASP = 4 (V) [2] + right
atrial pressure, where V is the peak velocity (in m/s) of
tricuspid regurgitation jet (TRV) [24]. Right atrial
pressure was estimated from characteristics of the in-
ferior vena cava [18]. If it was < 20 mm in diameter
and decreased during inspiration we added 5 mmHg,
≥20 mm we added 10 mmHg and 15 mmHg if no de-
crease of diameter during inspiration occurred.
Cardiopulmonary exercise testing
Patients were examined on a variable load supine bi-
cycle ergometer (model 8420; KHL Corp., Kirkland,
Washington) in Heidelberg as described previously
[25]. Workload was increased by 25 W every 2 min to
an exercise capacity or symptom limited maximum.
Peak VO2 was defined as the highest 30-s average
value of oxygen uptake during the last minute of the
exercise test.
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Ethics statement
The Ethics Committee of the Medical Faculty, Uni-
versity of Heidelberg had no obligation against the
conduct of the study (internal number S425/2016).
All data were anonymized and the study was con-
ducted in accordance with the amended Declaration
of Helsinki.
Statistical methods
Statistical analyses were conducted by two biometri-
cians (CF, NE). Data are described as means ± stand-
ard deviations or number and respective percentage.
Patients were divided into two groups according to
their RV size (larger or smaller RA and/or RV area
with value above or below the median of the complete
sample). A receiver operating characteristic (ROC)
curve analysis for RA and RV area with CI increase
below the median of the sample as outcome parameter
for further validation of the cut-off values was per-
formed. Quantitative characteristics between the two
groups including demographics, hemodynamics and
parameters of echocardiography and cardiopulmonary
exercise testing were compared by two-sided student’s
t-tests and nonparametric tests if needed. Frequency
distributions were compared by chi-square test or
Fisher’s exact test. A sensitivity analysis with a thresh-
old of 18 cm2 for RV area according to the cut-off pro-
posed by the guidelines17 was performed.
Right heart size (RA and RV area) was compared
between patients with higher vs. lower ΔCIexercise
(according to the median of the complete sample).
Differences of the course of CI and SV increase dur-
ing exercise between patients with smaller vs. larger RA
and RV area were analysed with mixed ANOVA. To in-
vestigate the associations between clinical parameters,
right heart size and output reserve, Pearson’s correl-
ation analysis was performed. To identify independent
predictors of RV output reserve, multivariate analysis
was performed by stepwise forward selection method of
logistic regression with the dichotomous variable of the
two groups (high or low ΔCIexercise) as outcome vari-
able. Parameters for correlation analysis included
demographics, hemodynamics, echocardiographic pa-
rameters and measures of cardiopulmonary exercise
testing according to clinical significance.
Pulmonary arterial compliance (PAC) was calculated
according the formula PAC = SV/ pulse pressure with
SV = CO/Heart rate and pulse pressure = sPAP-dPAP.
Stroke volume index was calculated with SVI = CI /
heart rate.
All tests were two-sided and a pointwise p-value of
0.05 was considered statistically significant. All ana-
lyses have been performed using IBM SPSS 23 (SPSS
Statistics V23, IBM Corporation, Somers, New York).
Results
Study population (Table 1)
We included 54 patients diagnosed with moderate to
severe PAH who fulfilled the inclusion criteria (21
males and 33 females, mean age 53 ± 15 years, 66.7%
WHO functional class II, 57.4% double combination
therapy; Table 1).
The study cohort presented with a median RA of 16cm2
and RV of 20 cm2. ROC curve analysis for RA and RV area
with CI increase < 2.1 l/min/m2 (median of the sample for
CI increase) further supported these proposed
cutoff-values of 16cm2 for RA and 20cm2 for RV area
(Fig. 1). For RV area, 20cm2 showed a sensitivity of 75%
and specificity of 73.1%; an RA area of 16cm2 presented
with a sensitivity of 75% and specificity of 57.7%.
Characteristics of groups with small and large right
heart size: According to the median RA and RV area, two
subgroups were defined for both RA and RV area: 1)
“enlarged right heart size” (RA >16cm2, RV >20cm2)
and 2) “normal/smaller right heart size” (RA ≤16cm2,
RV ≤20cm2; Table 2).
Both groups did not significantly differ in their
demographics (age and BMI), 6MWD, diffusion cap-
acity and peak VO2 for both RA and RV area.
PH-targeted treatment and distribution of combin-
ation treatment did also not significantly differ be-
tween groups (Table 2).
Patients with enlarged RA- (n = 21) and/or RV-area
(n = 24) had significantly higher mean, systolic and
diastolic pulmonary arterial pressures, mean pulmonary
vascular resistance, and NT-proBNP levels than patients
with normal or smaller right heart size.
Both groups of RA and RV size had well preserved
RV function at rest, represented by regular CI and SV,
even though PVR and mean pulmonary arterial pres-
sures were elevated in patients with enlarged right
heart size. Increase of CI during exercise was signifi-
cantly smaller in patients with enlarged RA- or
RV-areas (Fig. 2a and b). Furthermore, patients with
higher RV-area, but not RA-area, presented with a sig-
nificantly lower SV, SVI and pulmonary arterial com-
pliance at peak exercise than patients with smaller
RV-size (Table 2).
SV failed to increase in accordance with the
exposed exercise level in patients with large RA-
(p = 0.031) and/or RV area (p < 0.001; Fig. 3). Like-
wise, SVI was significantly higher in patients with
small right heart size, compared to patients with en-
larged RA and/or RV area (ANOVA RV p < 0.001,
RA p = 0.001). Furthermore, patients with smaller
RV, but not RA, presented with significantly higher
peak PAC than patients with RV area above the me-
dian (39.5 ± 11.2 ml/mmHg vs. 33.2 ± 15.3 ml/mmHg,
p = 0.027).
Fischer et al. Respiratory Research          (2018) 19:216 Page 3 of 13
Table 1 Characteristics of the study population
mean ± SD or n (%)
Demographics Age (years) 53 ± 14.65
BMI (kg/m2) 27.9 ± 5.69
Gender male n (%) 21 (38.9)
female n (%) 33 (61.1)
Diagnosis IPAH n (%) 31 (57.4)
HPAH n (%) 8 (14.8)
APAH n (%) 12 (22.2)
CTEPH n (%) 3 (5.6)
WHO functional class I n (%) 1 (1.9)
II n (%) 36 (66.7)
III n (%) 17 (31.5)
PAH-targeted medication Endothelin receptor antagonist 40 (74.1)
Phosphodiesterase-5-inhibitors 38 (70.4)
Soluble guanylate cyclase-stimulator 8 (13.0)
Prostanoids 6 (14.8)
Calcium channel blockers 2 (03.7)
Combination therapy
Mono n (%) 18 (33.3)
Double n (%) 31 (57.4)
Triple n (%) 5 (9.3)
RHC Rest mPAP (mmHg) 35.5 ± 11.69
sPAP (mmHg) 57.6 ± 20.87
dPAP (mmHg) 23 ± 7.87
PCWP (mmHg) 10 ± 3.54
PVR (dyn*sec*cm−5) 393.4 ± 235.03
CO (l/min) 5.8 ± 1.61
CI (l/min/m2) 3 ± 0.73
SVI (ml/m2) 41.1 ± 10.2
25 W Δ CI (l/min/m2) 1.2 ± 0.67
50 W Δ CI (l/min/m2) 2 ± 0.93
75 W Δ CI (l/min/m2) 2.6 ± 1.15
Peak mPAP (mmHg) 56.5 ± 15.91
sPAP (mmHg) 90.2 ± 28.36
dPAP (mmHg) 36.1 ± 11.56
CO (l/min) 10.2 ± 3.49
CI (l/min/m2) 5.3 ± 1.59
SVI (ml/m2) 47.2 ± 13.9
Echocardiography RV area (cm2) 20.1 ± 5.59
RA area (cm2) 16.8 ± 6.62
TAPSE (cm) 2.3 ± 0.38
Cardiopulmonary exercise
testing (CPET)
peak V’O2 (ml/min) 1126 ± 428.88
peak V’O2/kg (ml/min/kg) 14.1 ± 3.92
sPAP Max (mmHg) 81.8 ± 27.87
6-MWD (m) 423 ± 113.09
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Sensitivity analysis with a threshold of 18 cm2 for
RV area led to the same differences between groups
with small and large right heart size. Furthermore, CI
increase showed a statistically significant difference
for each workload level.
When dichotomising the patient cohort according
to RV output reserve (high and low ΔCIexercise) echo-
cardiography showed considerable differences in RV
and RA area (p = 0.003 and p = 0.019 respectively;
Fig. 4a and b).
Factors associated with right heart size and RV output
reserve (Tables 3 and 4)
Univariate analysis of right heart size and output
reserve In univariate regression analysis RV and RA
area were significantly correlated with NT-proBNP, sPAP,
CI during exercise, ΔCIPeak (Fig. 5) and with right heart
size (Table 3). RV area additionally significantly correlated
with mPAP at rest, CI at rest, PVR at rest and peak mPAP.
ΔCIexercise significantly positively correlated with age,
exercise capacity (6-MWD, peak oxygen consumption,
peak oxygen consumption/kg/min), hemodynamics (CO
at rest; peak CO and CI during exercise) and lung diffus-
ing capacity (transfer factor DLCOc SB and transfer co-
efficient DLCOc / VA) (Table 4). A negative correlation
was detected between ΔCIexercise and NT-proBNP, echo-
cardiographic parameters (sPAP, RA area, RV area) and
hemodynamics at rest (mPAP, PVR).
Multivariate analysis of output reserve Stepwise for-
ward selection of multivariate logistic regression ana-
lysis showed RV area to be the single independent
predictor for high or low ΔCIPeak (regression coeffi-
cient 0.863, p = 0.027).
Discussion
To the best of our knowledge this is the first study
showing that in patents with PAH enlarged RV- or
Fig. 1 ROC curve analysis. For RV area, 20cm2 showed a sensitivity of 75% and specificity of 73.1%; an RA area of 16cm2 presented with a sensitivity of
75% and specificity of 57.7%
Table 1 Characteristics of the study population (Continued)
mean ± SD or n (%)
Laboratory analysis NT-proBNP (pg/ml) 470.3 ± 856.74
Pulmonary function test (PFT) DLCOc SB (% Soll) 58.6 ± 17.25
DLCOc VA (% Soll) 70.42 ± 20.00
IPAH = idiopathic pulmonary arterial hypertension, HPAH = heritable PAH, APAH = associated PAH, CTEPH = chronic thromboembolic PH, RHC = right heart catheter,
BMI = Body Mass Index, RV = right ventricular, RA = right atrial, TAPSE = tricuspid annular plane systolic excursion, VO’2 = oxygen consumption, NT-proBNP = N-
terminal pro brain natriuretic peptide, DLCOc SB = diffusing capacity transfer factor, DLCOc / VA = diffusing capacity transfer coefficient, mPAP =mean pulmonary
arterial pressure, sPAP = systolic PAP, dPAP = diastolic PAP, PCWP = pulmonary capillary wedge pressure, PVR = pulmonary vascular resistance, CI = Cardiac Index,
SVI = stroke volume index, HR = heart rate, SV = stroke volume, Δ = difference
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RA areas (measured by echocardiography) were asso-
ciated with a significantly reduced RV pump func-
tion during exercise (lower ΔCIexercise) measured by
right heart catheterization. Furthermore, the study
revealed that PAH-patients with larger size of the
right heart had higher pulmonary arterial pressures,
pulmonary vascular resistance and NT-proBNP levels.
Patients with higher RV-areas presented with a sig-
nificantly lower stroke volume index and pulmonary
arterial compliance at peak exercise than patients
with smaller RV-size. RV area was identified as the
only independent predictor of RV output reserve
(lower ΔCIexercise). Thus, this study gives further evi-
dence that assessing the right heart size by imaging
Fig. 2 Course of CI during exercise according to RA (a) and RV area (b). Patients with smaller (RA≤median 16 cm2, RV ≤median 20 cm2, dotted
line) right heart size showed significantly higher CI during exercise, than patients with larger right heart size (RA >median 16 cm2, RV >median
20 cm2, dashed line; mixed ANOVA p < 0.001). Bars indicate 2 standard deviations of the mean
Fig. 3 Course of stroke volume increase during exercise according to RV area. Patients with smaller (≤ median 20 cm2, dotted line) RV area
showed significantly higher SV increase during exercise, than patients with larger RV area (> median 20 cm2; dashed line; mixed ANOVA p < 0.001).
Bars indicate the standard errors of the mean difference
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techniques as echocardiography gives further import-
ant clues to RV pump function and cardiopulmonary
hemodynamics.
Right heart size, pump function
This study confirms the results of previous studies
using MRI which showed that enlarged RV end systolic
and end-diastolic volumes were obtained in patients
with lower RV stroke volumes [12, 26]. However, in the
first previous MRI-study RV volumes were not directly
compared with pump function but with survival [26].
Large RV end-diastolic volume and SV at baseline were
associated with poorer prognosis. Further dilation of
RV with further decrease of SV during follow-up pre-
dicted a poor long-term outcome [26]. Most recently
these findings have been confirmed by an analysis of
the French PAH registry demonstrating that SVI and
right atrial pressure were independently associated with
death or lung transplantation at first follow-up after
initial PAH treatment [27].
Our study demonstrates for the first time a negative
relationship between right heart size and RV pump
function using 2-D-echocardiography for assessing the
RA- and RV-areas in the four chamber view and
hemodynamic values from right heart catheterization
at rest and during exercise. Patients with enlarged RV
area had significantly lower CI and SVI at rest and
during exercise. These patients had also higher mean
pulmonary arterial pressure, pulmonary vascular
resistance at rest and NT-proBNP levels which reflects
a more severe disease. The negative impact of RV-en-
largement was also demonstrated by a MRI-study
which showed in patients with increasing RV volumes
during follow-up a disease progression leading to
death or transplantation whereas patients with stable
RV volumes remained clinically stable [12]. Changes in
RV volumes were even more sensitive parameters for
deterioration than the repeated measurement of
hemodynamics which remained unchanged [12]. In
this study, patients with enlargement of RV volumes
had a decline of RV ejection fraction [12]. Two further
studies demonstrated a reduction in RV volumes by
targeted PAH-therapy, which suggests an improve-
ment of RV pump function [11, 28].
RV output reserve and right heart size
RV output reserve, defined in this study as increase
of CI during exercise measured by right heart
catheterization, is an emerging parameter which has
shown to be of prognostic importance in patients
with PH [13, 14]. In this study RV area was identified
as the only independent predictor of RV output re-
serve. This again shows that RV size may reflect the
impairment of RV pump function. We hypothesize
that increased PAC and reduced increase of RV out-
put during exercise in patients with larger RV and/or
RA areas, respectively is due to more severe pulmonary
vascular disease. A both reproducible and clinically
practical way to evaluate RV output reserve can be per-
formed by invasive measurements15. Further prospect-
ive studies have to be conducted to evaluate the
magnitude of the relation to right heart size and if non/
invasive assessment of RA- and RV area or volume are
useful for an estimation of RV output reserve.
Fig. 4 Difference of right heart size in patients with high and low ΔCI. Right heart size significantly differed between patients with high and low
ΔCIexercise according to the median of the complete sample of 2.1 L/min/m
2 (a) RA area p = 0.019, (b) RV area p = 0.003; identical p-values for
nonparametric and parametric testing)
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Advanced PAH with increased pulmonary load leads
to RV dilatation (heterometric adaptation) in order to
maintain SV6. In this study RV output reserve was
significantly linked to RV size.
Study limitations
The retrospective, single-center design of this study
with a rather small number of subjects limits the
study results. A higher sample size may have led to
identification of more independent factors in the
multivariate analysis.
Echocardiographic assessments of the right heart are
complicated by its complex shape and morphology.
Especially in obese patients, patients with chest wall
deformities or COPD, the correct assessment of RV
size and function becomes a challenging task. In this
respect, cardiac MRI becomes particularly appealing,
as it does provide a thorough assessment of right heart
size and function even in complicated conditions. In
our cohort, high quality recordings were used and no
comorbidities were interfering the test results. As the
determination of RA and RV area is a readily available
Table 3 Correlation analysis of right heart size and clinical parameters
Right atrial area Right ventricular area
n pearson’s R p-value n pearson’s R p-value
Univariate analysis
Age 54 0.193 0.162 54 - 0.048 0.209
Body mass index 54 0.181 0.190 54 0.733 0.129
6-min walking distance 53 - 0.108 0.441 53 - 0.121 0.387
NT-proBNP 53 0.539 < 0.001 * 53 0.538 < 0.001 *
Echocardiography
Systolic pulmonary arterial pressure 54 0.307 0.024 * 54 0.567 < 0.001 *
Right atrial area – 54 0.703 < 0.001 *
Right ventricular area 54 0.703 < 0.001 * –
Tricuspid annular plane systolic excursion 54 - 0.128 0.356 54 - 0.082 0.554
Cardiopulmonary exercise testing
Peak oxygen consumption (V’O2) 54 0.042 0.736 54 0.051 0.713
Peak oxygen consumption/kg (V’O2/kg) 54 - 0.199 0.149 54 - 0.227 0.099
Right heart catheter
rest
Mean pulmonary arterial pressure 54 0.176 0.202 54 0.544 < 0.001 *
Cardiac Output 54 - 0.028 0.839 54 - 0.052 0.709
Cardiac Index 54 - 0.209 0.129 54 - 0.281 0.040 *
Pulmonary arterial wedge pressure 54 0.025 0.857 54 - 0.101 0.467
Pulmonary vascular resistance 54 0.175 0.206 54 0.508 < 0.001 *
Stroke volume index 54 −0.244 0.076 54 −0.301 0.027 *
exercise
Mean pulmonary arterial pressure 54 0.097 0.486 54 0.419 0.002 *
Cardiac Output 54 - 0.177 0.200 54 - 0.223 0.104
Cardiac Index 54 - 0.344 0.011 * 54 - 0.427 0.001 *
Δ CI peak 54 - 0.313 0.021 * 54 - 0.376 0.005 *
Stroke volume index 54 −0.264 0.054 54 −0.407 0.002 *
Lung function / Diffusing capacity
DLCOc SB 48 - 0.052 0.723 48 - 0.003 0.982
DLCOc /VA 48 0.176 0.231 48 0.137 0.352
CI = Cardiac Index, NT-proBNP = N-terminal pro brain natriuretic peptide, DLCOc SB = diffusion capacity transfer factor, DLCOc /VA = diffusion capacity
transfer coefficient
* = significant at level 0.05
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assessment which is practicable in a good quality, its
application in clinical practice is more common com-
pared to cardiac MRI. Unfortunately, no MRI data is
available for this patient cohort to confirm the
hemodynamic data.
Invasive measurements, cardiopulmonary exercise
testing and echocardiographic parameters could not
be assessed in one single examination. In order to re-
duce the influence of inter-exam variations, we only
included patients that underwent all measures within
a time frame of 48 h. The assessment of CI may be
complicated by tricuspid insufficiency in patients with
PH. Due to the bidirectional blood flow through the
tricuspid valve CI may be overestimated in some pa-
tients, which may have influenced the results.
The correlation of right heart size and function to
TAPSE and other parameters and their prognostic
value should be investigated in a larger-scale study.
Table 4 Uni- and multivariate regression analysis of RV output reserve
Univariate analysis (Δ CI Peak) n pearson’s R p-value
Age 54 0.424 0.001 *
Body mass index 54 0.092 0.506
6 min walking distance 54 0.278 0.044 *
NT-proBNP 54 - 0.360 0.008 *
Echocardiography
Systolic pulmonary arterial pressure 54 - 0.462 < 0.001 *
Right atrial area 54 - 0.313 0.021 *
Right ventricular area 54 - 0.376 0.005 *
Tricuspid annular plane systolic excursion 54 0.065 0.64
Cardiopulmonary exercise testing
peak oxygen consumption (V’O2) 54 0.466 < 0.001 *
peak oxygen consumption/kg (V’O2/kg) 54 0.380 0.005 *
Right heart catheter
rest
mean pulmonary arterial pressure 54 - 0.288 0.035 *
Cardiac Output 54 0.282 0.039 *
Cardiac Index 54 0.223 0.106
Pulmonary arterial wedge pressure 54 - 0.016 0.906
pulmonary vascular resistance 54 - 0.366 0.006 *
exercise
mean pulmonary arterial pressure 54 - 0.073 0.598
Cardiac Output 54 0.839 < 0.001 *
Cardiac Index 54 0.894 < 0.001 *
Lung function / Diffusing capacity
DLCOc SB 48 0.361 0.012 *
DLCOc / VA 48 0.342 0.017 *
Multivariate analysis
Logistic Regression (stepwise forward selection)
Δ CI exrcise (dichotomous) Exp (B)
Right ventricular area 47 0.863 0.027 *
Linear Regression (stepwise forward selection)
Δ CI Peak (continuous) pearson’s R
Right ventricular area 47 - 0.360 0.003 *
Age 47 - 0.412 0.001 *
CI = Cardiac Index, NT-proBNP = N-terminal pro brain natriuretic peptide, DLCOc SB = diffusing capacity transfer factor, DLCOc / VA = diffusing capacity
transfer coefficient
* = significant at level 0.05, Exp (B) = Regression coefficient
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Conclusion
The study shows that assessment of right heart size is
important for RV functional characterization and may
be helpful since it reflects RV pump function and RV
output reserve. RV and RA area by 2-D echocardiog-
raphy represented a valuable and easily accessible indi-
cator of RV pump function at rest and during exercise.
Therefore, these results may be relevant for clinical
practice. RV output reserve should be considered as an
important clinical parameter. However, prospective
studies are needed for further evaluation.
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